Week of Mar. 6th-10th, 2017
Check back often for weekly updates
Breakthrough Prizes in Life Sciences ($3 million award, deadline May 31st, 2017). Each year, up to five Breakthrough Prizes in Life Sciences are awarded. One prize per year is for work contributing to the understanding of Parkinson’s Disease & Neurodegenerative Disorders. All prizes are individual and should recognize a single person’s contribution to the field of life sciences, with special attention to recent developments. Each laureate receives $3 million. The deadline for all 2018 prize nominations is May 31, 2017 at midnight PDT.
Alzheimer’s Drug Discovery Foundation – two opportunities:
· Prevention Beyond the Pipeline ($1.5 million award, three funding cycle Letter of Intent deadlines – May 19th, August 18th, and November 17th, 2017). The ADDF seeks to support prevention drug discovery not covered by most research funders or our current RFPs. Average Duration: 1-2 years. Average Award: Variable - Epidemiological Analyses: $50,000-$100,000; Preclinical Research: $150,000-$600,000; Clinical Trials: up to $1.5 million. Prevention Research Funding Priority Areas: Consortium of Cohorts for Alzheimer's Prevention Action (CAPA); Comparative Effectiveness Research; and, Cognitive Decline and Cognitive Reserve.
· Program to Accelerate Clinical Trials ($1.5 million award, three funding cycle Letter of Intent deadlines – May 19th, August 18th, and November 17th, 2017). The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease, related dementias, and cognitive aging. This program will fund exploratory Phase 0 microdosing studies that assess preliminary target engagement and PK, Phase I safety testing, Phase 2 biomarker-based proof-of-concept clinical trials in patients, as well as IND-enabling studies to accelerate new drugs into trials. Through this PACT RFP, the ADDF is also interested in supporting biomarker-based trials to validate putative mechanisms of action for targeted pharmacological and non-pharmacological approaches to prevention. Average Duration: Varies. Average Award: Up to $1.5 million. PACT Research Funding Priority Areas: Repurposing – Testing drugs approved for other indications in Alzheimer's disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a rational mechanism(s) of action. Novel therapies supported by preclinical in vivo data linking the therapeutic approach to Alzheimer’s disease or related dementias. With regards to potential drug targets: The ADDF is interested in novel targets that include, but are not limited to: Neuroinflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. The ADDF has limited interest in funding anti-amyloid approaches, including anti-amyloid aggregation programs, Abeta vaccine development and beta- or gamma-secretase inhibition programs. The ADDF also has limited interest in funding cholinesterase inhibitor programs.
Bill & Melinda Gates Foundation – multiple opportunities
· Grand Challenges Explorations – Health Systems Strengthening: Ensuring Effective Health Supply Chains (Award range: $100,000 to $1.1 M, deadline May 3rd, 2017). The health supply chain is comprised of people, processes, policies, technology and resources to ensure the right products reach the right place in the right condition. When effective, the supply chain is “the backbone” for access to safe and effective health products, and supports the goals of eliminating AIDS, TB and malaria, ending childhood vaccine-preventable deaths, and ensuring universal access to reproductive health services. An efficient supply chain also safeguards the significant financial investments on the procurement of health products by donors and country governments - estimates on donor-financed health products alone range from $7 - 10 billion dollars per year procured for low- and middle-income countries (LMIC). Yet, public health supply chains are often sub-optimal and unable to support achievement of the broader health goals of a country, due to a combination of failures relating to people, processes, technology or resources. Recognizing the need for innovation to tackle these supply chain barriers, the Gates Foundation and the U.S. Agency for International Development (USAID) have collaborated to issue this joint call for innovative and potentially transformative solutions with the potential to overcome key roadblocks to more effective supply chains in low- and middle-income countries. The Challenge: As noted, supply chains are an essential component supporting LMIC health systems in achieving the SDG goals and ensuring healthy lives for all. Some of the key challenges we see include: Last mile availability; Data driven performance management at all levels; Supply chain system design; Governance and accountability; Sustainable human capacity; and, Resource mobilization and supply chain operations financing. What we are looking for: The Foundation and USAID seek proposals that address challenges in effective health supply chains that are daring in premise, and clearly different from the approaches currently under investigation or employed. The solutions submitted to this topic could focus on an integrated health supply chain, or they could focus specifically on immunization and/or family planning supply chains and their respective programmatic goals. They must have the potential to be scaled up or reproduced in multiple settings. We encourage solutions that translate leading and best practices and solutions developed by the private sector (e.g. outside of health), as well as academic research and findings, to LMICs in a way that support their public health goals. Proposals must provide a strong rationale for the work proposed, demonstrating a clear understanding of country context and needs, and present a defined hypothesis and associated plan for how the idea would be tested or validated. Proposed ideas must ultimately be translatable to practical interventions accessible in resource-limited settings. Awards of $100,000 USD are made in Phase I. Phase I awardees have one opportunity to apply for a follow-on Phase II award of up to $1,000,000 USD. Proposals due by Wednesday, May 3, 2017 11:30 a.m. U.S. Pacific Daylight Time.
· Grand Challenges Explorations – Innovations for Integrated Diagnostics Systems (Award range: $100,000 to $1.1 M, deadline May 3rd, 2017). To date, the function of existing laboratory services in the developing world remains poor due to multiple factors including low instrument utilization rates, poor data management, supply chain issues, human resource challenges, low rates of results returned, poor quality systems, poor sample transportation systems and low quality specimens. The obstacles to making this a reality include but are not limited to the following areas: Connectivity; Sample Collection & Specimen Processing; Transportation & Distribution of Samples; and, Simplified/Streamlined Workflow. The Challenge: Our challenge is to make technological and process improvements in all the areas mentioned above, while at the same time paying attention to balance the cost trade-offs. Optimize transportation networks, and leverage distribution capabilities from other local services to improve sample transport logistics, timelines, and cost; Adapt selective centralized laboratory instrument platforms and assays that improve ease of use or robustness in developing world settings; and, Seek novel ways to implement interconnected laboratory networks that will efficiently track patients, specimens and data to and from various types of settings, ensuring quality diagnostic services are provided and can inform treatment and care decisions. Awards of $100,000 USD are made in Phase I. Phase I awardees have one opportunity to apply for a follow-on Phase II award of up to $1,000,000 USD. Proposals due by Wednesday, May 3, 2017 11:30 a.m. U.S. Pacific Daylight Time.
· Grand Challenges Explorations – New Approaches for Improving Timeliness of Routine Immunizations in Low-Resource Settings ($100,000 to $1.1M, deadline May 3rd, 2017). We are soliciting innovative ideas for improving timeliness of routine immunizations. We’re specifically seeking applications proposing innovative approaches that successfully improve timeliness while reducing missed opportunities for vaccination, respect gender and equity inequalities, and target hard to reach populations, such as nomadic or remote. Successful proposals will include details on the design and pilot testing of the approach in their application. The effectiveness of the proposed approach on timeliness should be evaluated in Phase I, and a clear plan for the impact of the approach on vaccine timeliness, completeness and coverage rates should be evaluated in Phase 2 if subsequent funding is awarded. Successful proposals will include: A clear hypothesis underlying the proposed approach to improve timeliness as well as documentation of timeliness (e.g. by a woman/child’s card, by health facility register that can track individual names of women/children vaccinated); Plan for evaluating the effectiveness of the approach in improving timeliness using established metrics; Outline of the design of the proposed approach to improve timeliness; and, A plan for evaluation of the impact of the approach on completeness and coverage rates, should Phase II funding be granted. Additionally, we will consider proposals identifying and testing approaches for improving timeliness of vaccines in low and middle income countries that support: Mothers and families seeking to overcome barriers regarding timeliness and completeness of routine immunization; Innovations that involve building on, disrupting, or adapting existing systems. Successful proposals will describe how their approach would work within existing health systems or what change would need to occur within health systems for their approach to be effective; and, Projects which constitute transformative rather than incremental improvements to improving timeliness that would be deliverable and scalable in low-income countries. Awards of $100,000 USD are made in Phase I. Phase I awardees have one opportunity to apply for a follow-on Phase II award of up to $1,000,000 USD. Proposals due by Wednesday, May 3, 2017 11:30 a.m. U.S. Pacific Daylight Time
· Grant Challenges Explorations – Wearables and Technology for Maternal, Neonatal, and Child Health Behavior Change (Award range: $100,000 to $1.1 M, deadline May 3rd, 2017). We seek wearable and/or sensor technologies that will improve the health of mothers and newborns by 1) increasing uptake of healthy behaviors and/or 2) facilitating research on maternal and neonatal interventions in low-resource settings. These new wearables and sensors should: Have a clear theory of change for catalyzing healthy maternal/newborn behaviors; Facilitate data collection for maternal-newborn health research with consideration of data privacy mechanisms; Be feasible within limited infrastructure environments (e.g. electricity, internet access, etc.); Consider projections and trends in technology in low-income settings (e.g. level of mobile phone technology); Consider the societal norms of target communities in low income countries; Consider the comfort and safety of the proposed user; Consider the sustainability and maintenance of the technology; Be easy to use; and, Incorporate a human-centered design approach. We seek proposals that: Are rooted in authentic understanding of and experience in local contexts; Bridge the gaps between user need and demand with technology; and, Are forward-thinking, leveraging upcoming and future technological trends. Awards of $100,000 USD are made in Phase I. Phase I awardees have one opportunity to apply for a follow-on Phase II award of up to $1,000,000 USD. Proposals due by Wednesday, May 3, 2017 11:30 a.m. U.S. Pacific Daylight Time.
Alzheimer’s Association – 2017 Part the Cloud Translational Research for Alzheimer’s disease Program ($400,000 award, deadline April 12th, 2017). Competition Objectives: In its sixth iteration, the Alzheimer's Association is pleased to announce the Part the Cloud Translational Research Funding initiative to increase the research efforts in Phase I and Phase II (Proof of Concept) clinical trials directed towards Alzheimer’s disease and related dementias internationally. Potential themes: This new grant mechanism aims to fill the gap in Alzheimer’s disease drug development by providing support for early phase studies of potential Alzheimer’s therapeutics or validation of biological markers of disease progression. Funding and award period: Each Part the Cloud Research grant is limited to a total of $400,000 (direct and indirect costs) for up to three years, minimum two years. However, in instances where a project may have a budget exceeding this value, please contact the Alzheimer’s Association at firstname.lastname@example.org for possible special programmatic or budgetary considerations. Requests in any given year may not exceed $300,000 (direct and indirect costs). Letters of Intent (LOI) must be received by 5:00 PM EASTERN STANDARD TIME, April 12, 2017.
Citizens United for Research in Epilepsy:
· 2017 CURE Epilepsy Award RFA ($250,000 award, Letter of Intent deadline April 19th, 2017). CURE’s investigator-initiated grants program seeks to push the envelope and accelerate promising research leading to disease-modifying breakthroughs for people living with epilepsy. CURE strongly encourages multidisciplinary, collaborative projects, especially those that include investigators and expertise from fields outside of epilepsy. The following 2017 priority areas reflect CURE’s focus on advances that have the potential to truly transform and save lives. Prevention and disease modification/elimination are critical goals and consistent with our mission. 2017 Priority areas: Transformative research to enhance our understanding of the cellular, molecular, genetic and systems-level mechanisms that lead to any of the epilepsies, facilitating the continued investigation of disease-modifying or preventative strategies; Innovative approaches that can prevent, modify and/or arrest the development of acquired epilepsy after stroke, tumor, viral infection, etc.; Research that will inform the development of novel therapies to prevent onset or halt the progression of the severe pediatric epilepsies; Research focused on new, effective treatments for the >30% of the epilepsy population who are pharmacoresistant; and, Novel research that furthers our understanding of the causes and ultimate elimination of SUDEP. Based on CURE’s current research objectives, lower priority will be given for research in the following areas: Research that focuses solely on a comorbid condition without also seeking to address/understand the accompanying epilepsy, and Research that focuses solely on improving localization of the epileptic seizure focus. Budget: Requests may be made for up to a total of $250,000 paid over 2 years. Letter of Intent Deadline April 19, 2017 – 9pm ET.
· Taking Flight Award ($100,000 award, Letter of Intent deadline April 19th, 2017). CURE seeks to promote the careers of young investigators to allow them to develop a research focus independent of their mentor(s). Researchers may propose basic or clinical CURE Awards studies, but this award mechanism is not intended to support clinical trials. Research that involves collaboration and a multidisciplinary approach is desirable. Applicant will be required to discuss how this avenue of research is independent from his or her mentor’s research, and will lead him or her to a path of independent epilepsy research. We encourage studies that will provide new directions for epilepsy therapy, prevention and, ultimately, a cure and that will allow applicants to collect the data necessary to support a National Institutes of Health grant application. Requests may be made for up to $100,000 for one year. Deadline for Receipt of LOI: April 19, 2017 - 9pm ET.
· Innovator Award ($50,000 award, Letter of Intent deadline April 19th, 2017). The CURE Innovator Award supports the exploration of a highly innovative, often risky new concept or untested theory that addresses an important problem relevant to epilepsy. The Innovator Award proposed research must reflect ideas substantially different from those being pursued by anyone in the epilepsy research field. The program is not intended to support the logical progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue radically unconventional, paradigm-shifting hypotheses. This award mechanism supports high-risk studies that have the potential to reveal entirely new areas of epilepsy research. Research completed through an Innovator Award must provide sufficient preliminary data to enable the PI to prove or disprove their groundbreaking, original, and/or unconventional hypothesis and have the potential, if the scope of work is successful, to move epilepsy research forward by leaps rather than by incremental steps. Areas of Interest: This program awards seed grants to researchers submitting innovative proposals that will provide new directions for epilepsy disease modifying therapies, prevention and, ultimately, a cure. We specifically encourage studies that may not be currently fundable by other agencies or other mechanisms because of their preliminary, innovative or unconventional nature. Requests may be made for up to $50,000 for one year. Letter of Intent Deadline: April 19, 2017–9pm ET.
American Federation for Aging Research – Irene Diamond Fund AFAR Research Postdoctoral Transition Awards in Aging ($150,000 award, deadline May 1st, 2017). The program provides up to seven two-year fellowships of $120,000, allowing for flexible and portable use of the funds, providing leverage to senior postdoctoral fellows to negotiate for junior faculty appointments and independent research programs either at their own or other institutions. A supplemental award of up to $30,000 may be available if the candidate successfully transitions to an independent junior faculty position within two years of completing the Diamond/AFAR Fellowship. The deadline for Letters of Intent is May 1, 2017.
Pfizer – 2017 ASPIRE Dermatology Disease Research Awards ($150,000 award, deadline May 5th, 2017). This ASPIRE program is part of Pfizer's commitment to supporting research in inflammatory and immune-mediated diseases in Dermatology. Mission: The mission of the ASPIRE program is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases. Background: Scientific research continues to advance our knowledge and understanding of inflammatory and immune-mediated diseases. The 2017 ASPIRE Dermatology Disease Research Awards will fund meritorious research proposals that have the potential to improve patient care. Areas of Focus: Clinical research related to inflammatory or immune-mediated diseases in dermatology; Approaches to improving communication among patients and healthcare providers (e.g., enduring materials, technological advancements, or web-based teaching programs); Health economic and outcomes research related to inflammatory or immune-mediated diseases in dermatology; Basic research in the etiology of inflammatory or immune-mediated diseases in dermatology including clarification of the intracellular immune cascade in the skin; Exploration of the role of PDE4 inhibition in inflammatory or immune mediated skin disease; Exploration of the role of PDE4 inhibition in itch; Use of clinical evaluation tools to document the severity of inflammatory or immune mediated skin disease and/or the impact of these conditions on quality of life or other patient reported outcomes; Approaches to improving adherence to topical therapy for atopic dermatitis; Approaches to improving management of inflammatory skin diseases (e.g. early therapy, prevention of flares, long-term maintenance, sequential treatment, bimodal therapy, etc.); and, Research related to, but not limited to, the use of topical PDE4 inhibition in the treatment of inflammatory or immune-mediated skin disorders with an unmet therapeutic need. Available Awards: The 2017 ASPIRE Dermatology Disease Research Awards are up to a maximum of $150,000 each. Applications must be received by May 5, 2017, 11:59 pm Eastern Time.
Huntington’s Disease Society of America – Huntington’s Disease Human Biology Project ($150,000 award, Letter of Intent deadline May 22nd, 2017). A one or two year grant mechanism to provide support for young scientists to work collaboratively with HD Clinics from around the world. Awards up to $75,000/year ($50,000 salary support and $25,000 research budget). All interested applicants must complete the required administrative information form and upload a completed Letter of Intent (LOI) no later than May 22, 2017 at 5:00 (EDT).
Breast Cancer Alliance, Inc. – 2018 Young Investigator Award ($125,000 award, deadline July 21st, 2017). To encourage a commitment to breast cancer research, the Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer research, and who are in the early stages of their career, to apply for funding for the Young Investigator Grant. This grant is open to applicants at institutions within the United States. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support. The grant provides salary support and project costs for a total of $125,000 (distributed over the two-year period). The research project must be directly related to the field of breast cancer. Areas of relevant research may include but are not limited to: diagnosis, etiology, immunology, genetics, therapies, prevention and clinical studies. Final applications must be emailed to email@example.com on or before July 21, 2017, followed by a hard copy mailed to the Breast Cancer Alliance office.
Children’s Heart Foundation – Clinical and Basic Science Research Grants Program ($100,000 award, deadline June 2nd, 2017). The Children's Heart Foundation supports clinical and basic science research in congenital heart disease, including, but not limited to the following areas: molecular genetics, biochemistry, pharmacology, devices and procedural research (cardiac catheterization and surgery), and long-term care of adults with congenital birth defects. CHF funding will be limited to two years (consecutive or otherwise). No single project may receive more than $100,000 in CHF funds during any calendar year.
Bruce and Cynthia Sherman Charitable Foundation – Call for Nominations: 2017 Sherman Prize ($100,000 award, deadline April 30th, 2017). The Sherman Prize recognizes and rewards healthcare providers, medical researchers, public health advocates, and educators who are advancing patient care, medical research, public service, and professional/public education on behalf of the more than three million Americans living with Crohn’s disease and ulcerative colitis, also known as the inflammatory bowel diseases (IBDs). Two Sherman Prizes of $100,000 each are awarded annually to individuals with extraordinary records of achievement addressing the challenges of Crohn’s and colitis, and a $25,000 Sherman Emerging Leader Prize is awarded to an individual who demonstrates high potential. Nomination Process and Eligibility Nominations for the Sherman Prize will be accepted at www.shermanprize.org through April 30, 2017.
Howard Hughes Medical Institute - Investigator Program (Award: Seven Year Full Salary Coverage for PI and a comprehensive benefits package to PI and other eligible employees – see eligibility criteria for further details). Through periodic competitions, HHMI accepts applications from researchers at more than 200 research institutions across the United States, with the aim of identifying individuals who have the potential to make significant contributions to science. Investigators continue to be based at their host institutions; however, HHMI investigators and some of their laboratory personnel are Institute employees and are supported by HHMI field offices throughout the country. Each investigator receives his or her full salary, benefits, and a research budget from HHMI. Appointment is for a seven-year term (previously five years, prior to February, 2017), which may be renewed after an exacting review process. Application Deadline: June 27, 2017, 3 p.m. EDT